Buoninfante Alessandra, Andeweg Arno, Genov Georgy, Cavaleri Marco
Public Health Threats, European Medicines Agency, Amsterdam, The Netherlands.
Pharmacovigilance Office, European Medicines Agency, Amsterdam, The Netherlands.
NPJ Vaccines. 2024 Jun 28;9(1):122. doi: 10.1038/s41541-024-00893-1.
Following the start of the COVID-19 vaccination campaign, the adverse events of myocarditis and pericarditis were linked mainly to mRNA COVID-19 vaccines by the regulatory authorities worldwide. COVID-19 vaccines have been administered to several million people and the risk of myocarditis post COVID-19 vaccination has been characterised in great detail. At the present time the research data available are scarce and there is still no clear understanding of the biological mechanism/s responsible for this disease. This manuscript provides a concise overview of the epidemiology of myocarditis and the most prominent mechanistic insights in the pathophysiology of the disease. Most importantly it underscores the needed next steps in the research agenda required to characterize the pathophysiology of this disease post-COVID-19 vaccination. Finally, it shares our perspectives and considerations for public health.
自新冠病毒疫苗接种运动开始以来,全球监管机构将心肌炎和心包炎等不良事件主要与新冠病毒mRNA疫苗联系起来。新冠病毒疫苗已接种给数百万人,接种新冠病毒疫苗后发生心肌炎的风险已得到详细描述。目前可获得的研究数据稀缺,对于导致这种疾病的生物学机制仍没有清晰的认识。本手稿简要概述了心肌炎的流行病学以及该疾病病理生理学中最突出的机制见解。最重要的是,它强调了在新冠病毒疫苗接种后表征该疾病病理生理学所需的研究议程中的后续步骤。最后,它分享了我们对公共卫生的观点和考虑。